Laying a foundation for future growth
Posted by
22-Feb-2018
The secret to constructing a sustainable and stable building is good foundations. This requires care, expertise and a commitment to investing in the future.
At UCB, we take this approach when preparing our company for future growth. As our 2017 Full Year Report illustrates, the company performed well last year and we have also been working to ensure strong results in the years to come.
This is something I am emphasising this week when speaking with analysts and investors: yes, the 2017 results are great in their own right, but the bigger picture is how we use this to invest in UCB’s future to enable growth, sustainability and profitability.
The report shows positive growth momentum of UCB’s core products, driving top and bottom line growth. Underlying profitability (rEBITDA) increased by 33% to € 1.375 million – thanks to solid revenue growth, efficient resource allocation and tight cost control. This means that we successfully reached our target of a 30% rEBITDA margin one year ahead of schedule.
For 2018, revenue is expected to reach € 4.5 - 4.6 billion, underlying profitability should be € 1.3 - 1.4 billion, and core earnings per share (EPS) of € 4.30 - 4.70 are expected.
The report also provides an update on our R&D pipeline, pointing to strong positive results for a number of new molecules and existing products – and exciting new additions from “R” to “D”!. UCB will invest in its early and late-stage innovative development pipeline, while selectively bringing in external opportunities to build new growth post 2021.
For more information on this or related matters, don’t hesitate to contact me and the IR team. As usual, we’re “hitting the road” now: see us at several occasions in London, Paris and Brussels during March. Looking forward to continuing the dialog with you!
At UCB, we take this approach when preparing our company for future growth. As our 2017 Full Year Report illustrates, the company performed well last year and we have also been working to ensure strong results in the years to come.
This is something I am emphasising this week when speaking with analysts and investors: yes, the 2017 results are great in their own right, but the bigger picture is how we use this to invest in UCB’s future to enable growth, sustainability and profitability.
The report shows positive growth momentum of UCB’s core products, driving top and bottom line growth. Underlying profitability (rEBITDA) increased by 33% to € 1.375 million – thanks to solid revenue growth, efficient resource allocation and tight cost control. This means that we successfully reached our target of a 30% rEBITDA margin one year ahead of schedule.
For 2018, revenue is expected to reach € 4.5 - 4.6 billion, underlying profitability should be € 1.3 - 1.4 billion, and core earnings per share (EPS) of € 4.30 - 4.70 are expected.
The report also provides an update on our R&D pipeline, pointing to strong positive results for a number of new molecules and existing products – and exciting new additions from “R” to “D”!. UCB will invest in its early and late-stage innovative development pipeline, while selectively bringing in external opportunities to build new growth post 2021.
For more information on this or related matters, don’t hesitate to contact me and the IR team. As usual, we’re “hitting the road” now: see us at several occasions in London, Paris and Brussels during March. Looking forward to continuing the dialog with you!
Leave a Comment